Diakonos Oncology Corporation
Clinical trials sponsored by Diakonos Oncology Corporation, explained in plain language.
-
New immune therapy aims to extend life in deadly brain cancer
Disease control Recruiting nowThis study tests a new treatment called DOC1021, made from a patient's own immune cells, combined with standard therapy for newly diagnosed glioblastoma, an aggressive brain cancer. About 180 adults will either receive the immune therapy plus standard care or standard care alone.…
Phase: PHASE2 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New immune therapy targets Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapies. The treatment uses a patient's own immune cells, trained to attack their specific tumor, along with an immune-boosting injection. The goal is to see if …
Phase: PHASE1, PHASE2 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated May 07, 2026 18:43 UTC